Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.88 - $26.62
Previous CloseN/A
Volume146.35K
Average Volume (3M)224.66K
Market Cap
$197.18M
Enterprise Value-$140.49M
Total Cash (Recent Filing)$297.30M
Total Debt (Recent Filing)$8.75M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 06, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding35,850,037
10 Day Avg. Volume188,547
30 Day Avg. Volume224,662
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.71
Enterprise Value/Revenue-36.37
Enterprise Value/Gross Profit-36.92
Enterprise Value/Ebitda1.72
Forecast
1Y Price Target
$5.00Price Target Upside-9.09% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe first participant dosed in the Phase 1 study of BGE-102, a brain-penetrant NLRP3 inhibitor, marks a significant step forward for the company.
Financial PositionBioAge Labs has a strong cash position of $313.4 million, which is expected to support operations through 2029.
Strategic PartnershipsDiscovery collaborations with major companies like Novartis and Lilly are progressing well, focusing on novel targets related to aging and exercise.
Bears Say
EarningsThe net loss per share reported was $0.60, greater than the estimated loss of $0.41 per share, indicating financial challenges.
Financial PerformanceBioAge reported a net loss of $21.6 million for the second quarter, surpassing the estimated net loss of $15.0 million, primarily due to higher-than-expected operating expenses.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $2.88 and its highest was $26.62 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $197.18M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 22 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.118.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Overvalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.58.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 35,850,037 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went down -0.231%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
BioAge Labs, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$5.00 (-9.09% Downside)
$5.00 (-9.09% Downside)
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-74.65%
12-Months-Change
Fundamentals
Return on Equity
-35.88%
Trailing 12-Months
Asset Growth
95.95%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
BIOA Stock 12 Month Forecast
Average Price Target
$5.00
▼(-9.09% Downside)
Technical Analysis
Ironwood Pharma
―
Lifecore Biomedical
―
China SXT Pharmaceuticals
―
Journey Medical Corp
―
Incannex Healthcare Limited Sponsored ADR
―
Ownership Overview
13.57% Insiders
5.29% Mutual Funds
43.25% Other Institutional Investors
31.07% Public Companies and
Individual Investors